Skip to content
GLP-1 Scorecard
Menu
Site position #433

MEDVidi

Published by GLP-1 ScorecardUpdated

MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus Saxenda, Qsymia and phentermine.

Visit MEDVidiWe may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Yes

Line MEDVidi up against its closest alternatives.

Factor breakdown

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and policies may differ from those used in the marks. See the methodology.

Cost value45/100
Dose & formulation53/100
Clinical oversight77/100
Labs & monitoring62/100
Fulfillment59/100
Contract terms55/100

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

What to consider

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated

Bottom line — Grade C

Best for: People who want a licensed provider to prescribe brand GLP-1 they fill with insurance.

Site position #433 of 541. Commercial relationships affect placement, not the score. See our featured provider, CoreAge Rx (#1), for comparison.

Closest here

The rankings grading nearest MEDVidi — the realistic shortlist.

The 21 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect MEDVidi's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on MEDVidi's site. Not medical advice; see our disclosure.

← Back to the scorecard